BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

IBI362: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Innovent Biologics (Suzhou) Co. Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)active not recruiting479

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityObesityactive not recruiting98
2026-09-24 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityObesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Eactive not recruiting141
2026-09-23P2Innovent Biologics (Suzhou) Co. Ltd.NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatohepatitis (MASH)active not recruiting181
2026-08-01 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityOverweight; Obesity; Hypertensiverecruiting336

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.